Application of tetracycline derivative in preparing sensitizing drug for radiotherapy

A technology of tetracyclines and derivatives, which is applied in the field of radiosensitization drugs, can solve the problems of no CMT-8 radiosensitization reports, and achieve the effect of improving radiosensitivity

Inactive Publication Date: 2011-10-05
SUZHOU UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] There is no report on the radiosensitization of CMT-8 in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tetracycline derivative in preparing sensitizing drug for radiotherapy
  • Application of tetracycline derivative in preparing sensitizing drug for radiotherapy
  • Application of tetracycline derivative in preparing sensitizing drug for radiotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] (1) Cell culture: Cells were cultured in DMEM medium containing 10% calf serum, glutamine and 1 million U / L penicillin and streptomycin. Cells were placed in 5% CO 2 , cultured in a 37°C incubator, subcultured once every 2-3 days, and the cells in the logarithmic growth phase were used for experiments.

[0020] (2) HeLa cells (6×10 4 / mL) were inoculated into a 96-well plate, and after culturing for 24 hours, different concentrations of CMT-8 were added. After continuing to culture for 24 hours, add 20 μL MTT (5 μg / mL) to the cell culture medium and continue to culture for 4 hours. Aspirate the culture medium, add 150 μL DMSO to each well, and shake gently on a shaker for 10 minutes. Finally, the optical density was detected by a microplate reader (A570 nm / A630 nm absorbance value), and the cell survival rate was calculated by the method of cell survival rate=dosage group value / control group value×100%, and the obtained results were as follows: figure 1 As shown, CM...

Embodiment 2

[0022] (1) cell culture is the same as embodiment one;

[0023] (2) HeLa cells (6×10 4 / mL) were inoculated into 96-well plates, and HeLa cells were treated with different concentrations (0, 1, 2, 3, 4, 5 μmol / L) of CMT-8 for 24 hours, and 6 parallel wells were set up for each concentration, and then 6 Gy of After χ-ray irradiation, continue to incubate for 24 hours, add 20 μl MTT (5 μg / mL) to the cell culture medium and continue to incubate for 4 hours. Aspirate the culture medium, add 150 μL DMSO to each well, and shake gently on a shaker for 10 minutes. Finally, a microplate reader (A570 nm / A630 nm absorbance value) was used to detect the optical density and calculate the cell survival rate. The obtained results were as follows: figure 2 As shown, the treatment of CMT-8 (< 5 μmol / L) at a concentration without toxic side effects can significantly increase the radiotherapy sensitivity of HeLa cells, and shows a dose-dependent radiation sensitization effect: after 1 μmol / L ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of sensitizing drugs for radiotherapy, and relates to a new application of a tetracycline derivative, in particular to an application of the tetracycline derivative in preparing a sensitizing drug for radiotherapy. The structural formula of the tetracycline derivative is as shown in the specification. The tetracycline derivative disclosed by the invention can beused for preparing a sensitizing drug for radiotherapy, and can improve the radiosensitivity of tumor cells under low concentration of the tetracycline derivative without toxic side effects.

Description

technical field [0001] The invention belongs to the field of radiotherapy sensitizing drugs, and relates to a new application of tetracycline derivatives, that is, the application in the preparation of radiotherapy sensitizing drugs. Background technique [0002] Cervical cancer is one of the most common malignant tumors in women, accounting for more than half of female reproductive system malignant tumors. At present, more than 200,000 women worldwide die of cervical cancer every year. There are 131,500 newly discovered cases in my country every year, and the general trend is that the rural areas are higher than the urban mountain areas and the plains. The mortality rate of cervical cancer in my country ranks first in the total cancer mortality rate. Domestic women suffering from cervical cancer are between 36 and 50 years old, accounting for more than 50% of the total number of patients. Cervical cancer cases are also showing a younger trend. Therefore, the treatment of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/65A61P35/00A61P15/00
Inventor 樊赛军申琳棱
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap